

Fludarabine Based RIC for Bone Marrow Failure Syndromes

NCT02928991

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Children's Hospital of Philadelphia
Enrollment	25 participants

Key Eligibility Criteria

Inclusion (32)

- Patients 0-22 years with acquired aplastic anemia or a diagnosed inherited bone marrow failure syndrome, and a fully Human leukocyte antigen (HLA)-matched (10/10) related donor.
- Patient:
- Ages 0-22 years at time of enrollment
- Diseases:
- Patients with severe or very severe acquired AA, defined by:
... and 27 more (see full listing online)

Exclusion (6)

- Uncontrolled bacterial, viral or fungal infections
- HLA matched related donor unable to donate bone marrow.
- No eligible fully HLA-matched related donor
- Pregnant females
- Patients with a clinical diagnosis of Myelodysplastic syndrome (MDS) defined by combination of bone marrow dysplasia and classic cytogenetic lesion (Monosomy 7, Trisomy 8 eg.), with or without excess blasts.
... and 1 more (see full listing online)

Locations (1 total)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

<https://clinicaltrials.gov/study/NCT02928991>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).